首页 > 最新文献

BMC Complementary and Alternative Medicine最新文献

英文 中文
Varieties of silence – a mixed-methods study exploring reasons and justifications for nondisclosure of the use of complementary therapies to physicians in Finland 沉默的多样性--一项混合方法研究,探讨芬兰医生不透露使用补充疗法的原因和理由
2区 医学 Q1 Medicine Pub Date : 2024-09-19 DOI: 10.1186/s12906-024-04640-w
Pauliina Aarva, Tiina Väänänen, Maija Pyykkönen, Tiia-Tuulia Kankkunen
In health care, two in three users of complementary therapies (CT) stay silent about their CT use. Disclosure of CT use to physicians is important for patient safety, participation, and shared decision-making. Common reasons for CT nondisclosure include patients´ expectations of physicians’ unaccepting response to disclosure, physicians not asking, and patients believing it is unnecessary. This study aimed to increase understanding of patient silence. We investigated how the reasons for nondisclosure of CT use reported by CT users were associated with the frequency of CT disclosure and how these associations and reported justifications to keep silent reflect patient silence among the study participants. This mixed-methods study used existing data from the non-probability-based online survey (n = 6802) targeted to CT users among the general population in Finland. A qualitative structured tabular thematic analysis was conducted for the selected 342 brief texts describing the reasons and justification for not telling physicians about CT use. The associations between the frequency of CT disclosure and the reasons for CT nondisclosure were analysed by crosstabulations and binary logistic regression analysis with SPSS (v28). Three types of patient silence were revealed. Avoidant silence illustrates the respondents coping with the fear of unwanted response from a physician and avoiding the expected negative consequences of CT disclosure. Precautionary silence exemplifies respondents striving to prevent the reoccurrence of previously experienced frustration of wishes to be seen and heard as CT users. Conditional silence portrays the self-confidence of respondents who assessed their need to disclose CT use to physicians on a case-by-case basis. Silence, for some patients, may serve as a way of warding off past and possible future fears and frustrations related to CT disclosure. It is important to recognise different types of patient silence related to CT disclosure to enhance patient participation and shared decision-making in health care. Efforts are needed to provide health policy decision-makers with information about CT users’ lived experiences with CT communication in health care.
在医疗保健领域,每三位辅助疗法(CT)使用者中就有两位对自己使用 CT 的情况保持沉默。向医生披露使用 CT 的情况对于患者的安全、参与和共同决策非常重要。不透露 CT 使用情况的常见原因包括:患者认为医生不会接受患者透露 CT 使用情况;医生没有询问;患者认为没有必要。本研究旨在加深对患者沉默的理解。我们调查了 CT 使用者所报告的不披露 CT 使用情况的原因与 CT 披露频率之间的关联,以及这些关联和所报告的保持沉默的理由如何反映出研究参与者中患者的沉默。这项混合方法研究使用了非概率在线调查(n = 6802)中的现有数据,调查对象是芬兰普通人群中的 CT 使用者。研究人员对所选的 342 个简短文本进行了定性结构化表格主题分析,这些文本描述了不告诉医生使用 CT 的原因和理由。使用 SPSS (v28) 进行交叉统计和二元逻辑回归分析,分析了 CT 披露频率与不披露 CT 的原因之间的关联。研究揭示了患者沉默的三种类型。回避型沉默说明受访者害怕医生不想要的回应,并避免披露 CT 的预期负面影响。预防性沉默说明受访者努力防止以前经历过的挫折再次发生,即希望作为 CT 使用者被看到和听到。有条件的沉默体现了受访者的自信,他们根据具体情况评估是否需要向医生披露使用 CT 的情况。对于某些患者来说,沉默可能是一种抵御过去和未来可能出现的与 CT 披露相关的恐惧和挫折的方式。重要的是要认识到与 CT 披露相关的不同类型的患者沉默,以加强患者在医疗保健中的参与和共同决策。需要努力为医疗政策决策者提供有关 CT 使用者在医疗保健中与 CT 沟通的生活经历的信息。
{"title":"Varieties of silence – a mixed-methods study exploring reasons and justifications for nondisclosure of the use of complementary therapies to physicians in Finland","authors":"Pauliina Aarva, Tiina Väänänen, Maija Pyykkönen, Tiia-Tuulia Kankkunen","doi":"10.1186/s12906-024-04640-w","DOIUrl":"https://doi.org/10.1186/s12906-024-04640-w","url":null,"abstract":"In health care, two in three users of complementary therapies (CT) stay silent about their CT use. Disclosure of CT use to physicians is important for patient safety, participation, and shared decision-making. Common reasons for CT nondisclosure include patients´ expectations of physicians’ unaccepting response to disclosure, physicians not asking, and patients believing it is unnecessary. This study aimed to increase understanding of patient silence. We investigated how the reasons for nondisclosure of CT use reported by CT users were associated with the frequency of CT disclosure and how these associations and reported justifications to keep silent reflect patient silence among the study participants. This mixed-methods study used existing data from the non-probability-based online survey (n = 6802) targeted to CT users among the general population in Finland. A qualitative structured tabular thematic analysis was conducted for the selected 342 brief texts describing the reasons and justification for not telling physicians about CT use. The associations between the frequency of CT disclosure and the reasons for CT nondisclosure were analysed by crosstabulations and binary logistic regression analysis with SPSS (v28). Three types of patient silence were revealed. Avoidant silence illustrates the respondents coping with the fear of unwanted response from a physician and avoiding the expected negative consequences of CT disclosure. Precautionary silence exemplifies respondents striving to prevent the reoccurrence of previously experienced frustration of wishes to be seen and heard as CT users. Conditional silence portrays the self-confidence of respondents who assessed their need to disclose CT use to physicians on a case-by-case basis. Silence, for some patients, may serve as a way of warding off past and possible future fears and frustrations related to CT disclosure. It is important to recognise different types of patient silence related to CT disclosure to enhance patient participation and shared decision-making in health care. Efforts are needed to provide health policy decision-makers with information about CT users’ lived experiences with CT communication in health care.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2 马来西亚药用植物产品 SKF7® 对 SARS-CoV-2 的体外药效研究
2区 医学 Q1 Medicine Pub Date : 2024-09-11 DOI: 10.1186/s12906-024-04628-6
Mohd Ridzuan Mohd Abd Razak, Nur Hana Md Jelas, Nor Azrina Norahmad, Norazlan Mohmad Misnan, Amirrudin Muhammad, Noorsofiana Padlan, Muhammad Nor Farhan Sa’at, Murizal Zainol, Ami Fazlin Syed Mohamed
In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.
2020 年初,COVID-19 大流行促使研究人员寻找新的疗法,包括重新利用药用植物产品,重点是直接作用抗病毒和宿主导向疗法。在本研究中,我们对标准化的马兰头提取物(SKF7®)进行了体外研究,重点研究其抗SARS-CoV-2和抗炎活性。在SARS-CoV-2感染的Vero E6细胞和SARS-CoV-2感染的A549细胞中,分别通过基于细胞病理效应的检测和RT-qPCR对SKF7®的抗SARS-CoV-2潜力进行了评估。对 SKF7® 的 S1-ACE2 相互作用和 3CL 蛋白酶活性进行了靶标检测。一氧化氮抑制和 TLR2/TLR4 受体阻断试验评估了 SKF7® 的抗炎活性。SKF7® 可抑制 Vero-E6 细胞中野生型武汉病毒(EC50 为 21.99 µg/mL)和欧米茄病毒(EC50 为 16.29 µg/mL)的 SARS-CoV-2 感染。SKF7® 还能抑制野生型 SARS-CoV-2 在 A549 细胞中的感染(EC50 值为 6.31 µg/mL)。SKF7® 能显著抑制 3CL 蛋白酶的活性。SKF7® 可抑制 LPS 诱导的 TLR4 反应,其 EC50 值为 16.19 µg/mL。总之,我们的体外研究强调了 SKF7® 的抗 SARS-CoV-2 和抗炎潜力。未来的临床前体内研究应侧重于 SKF7® 在影响 COVID-19 发病机制方面的抗病毒和免疫调节潜力。
{"title":"In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2","authors":"Mohd Ridzuan Mohd Abd Razak, Nur Hana Md Jelas, Nor Azrina Norahmad, Norazlan Mohmad Misnan, Amirrudin Muhammad, Noorsofiana Padlan, Muhammad Nor Farhan Sa’at, Murizal Zainol, Ami Fazlin Syed Mohamed","doi":"10.1186/s12906-024-04628-6","DOIUrl":"https://doi.org/10.1186/s12906-024-04628-6","url":null,"abstract":"In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142180625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights into free radicals scavenging, α-Amylase inhibition, cytotoxic and antifibrotic activities unveiled by Peganum harmala extracts 揭示牛膝提取物清除自由基、抑制α-淀粉酶、细胞毒性和抗纤维化活性的奥秘
2区 医学 Q1 Medicine Pub Date : 2024-08-12 DOI: 10.1186/s12906-024-04602-2
Nidal Jaradat, Mohammed Hawash, Majid Sharifi-Rad, Ali Shakhshir, Shorooq Sobuh, Fatima Hussein, Linda Issa, Sondos Hamamrhe, Eman Al-Sheikh, Alaa Naser Ibrahim
Peganum harmala L. is used in traditional medicine to treat several health ailments. Hence, the present work aimed to investigate the DPPH free radical scavenging, α-amylase, cytotoxic, and antifibrotic effects of the hydrophilic extract and fixed oil obtained from P. harmala seeds. The hydrophilic extract and fixed oil of P. harmala were assessed for their abilities to scavenge DPPH free radicals and inhibit α-amylase using reference bioassays. The cytotoxicity was assessed on several cancer and normal cell lines, including B16F1, Caco-2, COLO205, HeLa, Hep 3B and Hep G2, MCF-7, and HEK-293 T cells. The MTS assay was used to evaluate the antifibrotic capabilities utilizing the human hepatic stellate (LX-2) cell line. P. harmala plant fixed oil has potent DPPH free radical scavenging activity with an IC50 dose of 79.43 ± 0.08 µg/ml. Besides, the hydrophilic extract has a poor anti-α-amylase effect compared with the antidiabetic drug Acarbose, with IC50 doses of 398 ± 0.59 and 25.11 ± 1.22 µg/ml, respectively. In addition, the growth of MCF-7, Hep3B, HepG2, HeLa, COLO205, CaCo2, B16F1, and HeK293t was inhibited by P. harmala hydrophilic extract with IC50 doses of 121.34 ± 1.71, 268.3 ± 0.75, 297.20 ± 1.00, 155.60 ± 1.14, 150.01 ± 0.51, 308.35 ± 0.53, 597.93 ± 1.36, and 5.38 ± 0.99 µg/ml, respectively. In addition, at 1000 µg/ml, 5-Fluorouracil reduced fibrosis cells by 0.089%, while the hydrophilic extract decreased the number of LX-2 cells by 5.81%. P. harmala plant-fixed oil exhibits potential antioxidant properties. While the hydrophilic extract showed limited effectiveness as an anti-α-amylase agent and demonstrated notable cytotoxic effects against various tested cancer cell lines. Furthermore, this extract significantly reduces the number of LX-2 fibrotic cells. These findings emphasize the therapeutic potential of these products in managing various health disorders and warrant further investigation into their mechanisms of action and clinical applications.
Peganum harmala L.在传统医学中被用于治疗多种疾病。因此,本研究旨在调查从 P. harmala 种子中提取的亲水提取物和固定油的 DPPH 自由基清除、α-淀粉酶、细胞毒性和抗纤维化作用。采用参考生物测定法评估了哈马拉种子亲水提取物和固定油清除 DPPH 自由基和抑制 α 淀粉酶的能力。对几种癌症和正常细胞系进行了细胞毒性评估,包括 B16F1、Caco-2、COLO205、HeLa、Hep 3B 和 Hep G2、MCF-7 和 HEK-293 T 细胞。MTS 试验用于评估人肝星状细胞(LX-2)的抗纤维化能力。哈马拉植物固定油具有强效的 DPPH 自由基清除活性,其 IC50 剂量为 79.43 ± 0.08 µg/ml。此外,与抗糖尿病药物阿卡波糖相比,亲水提取物的抗α-淀粉酶效果较差,IC50剂量分别为 398 ± 0.59 和 25.11 ± 1.22 µg/ml。此外,哈马拉亲水提取物还能抑制 MCF-7、Hep3B、HepG2、HeLa、COLO205、CaCo2、B16F1 和 HeK293t 的生长,IC50 剂量分别为 121.34 ± 1.71、268.3 ± 0.75、297.20 ± 1.00、155.60 ± 1.14、150.01 ± 0.51、308.35 ± 0.53、597.93 ± 1.36 和 5.38 ± 0.99 µg/ml。此外,在 1000 µg/ml 的浓度下,5-氟尿嘧啶可使纤维化细胞数量减少 0.089%,而亲水提取物可使 LX-2 细胞数量减少 5.81%。哈马拉植物固定油具有潜在的抗氧化特性。亲水萃取物作为一种抗α-淀粉酶制剂显示出有限的有效性,并对各种测试的癌细胞株显示出显著的细胞毒性作用。此外,这种提取物还能明显减少 LX-2 纤维化细胞的数量。这些发现强调了这些产品在治疗各种健康疾病方面的潜力,值得进一步研究其作用机制和临床应用。
{"title":"Insights into free radicals scavenging, α-Amylase inhibition, cytotoxic and antifibrotic activities unveiled by Peganum harmala extracts","authors":"Nidal Jaradat, Mohammed Hawash, Majid Sharifi-Rad, Ali Shakhshir, Shorooq Sobuh, Fatima Hussein, Linda Issa, Sondos Hamamrhe, Eman Al-Sheikh, Alaa Naser Ibrahim","doi":"10.1186/s12906-024-04602-2","DOIUrl":"https://doi.org/10.1186/s12906-024-04602-2","url":null,"abstract":"Peganum harmala L. is used in traditional medicine to treat several health ailments. Hence, the present work aimed to investigate the DPPH free radical scavenging, α-amylase, cytotoxic, and antifibrotic effects of the hydrophilic extract and fixed oil obtained from P. harmala seeds. The hydrophilic extract and fixed oil of P. harmala were assessed for their abilities to scavenge DPPH free radicals and inhibit α-amylase using reference bioassays. The cytotoxicity was assessed on several cancer and normal cell lines, including B16F1, Caco-2, COLO205, HeLa, Hep 3B and Hep G2, MCF-7, and HEK-293 T cells. The MTS assay was used to evaluate the antifibrotic capabilities utilizing the human hepatic stellate (LX-2) cell line. P. harmala plant fixed oil has potent DPPH free radical scavenging activity with an IC50 dose of 79.43 ± 0.08 µg/ml. Besides, the hydrophilic extract has a poor anti-α-amylase effect compared with the antidiabetic drug Acarbose, with IC50 doses of 398 ± 0.59 and 25.11 ± 1.22 µg/ml, respectively. In addition, the growth of MCF-7, Hep3B, HepG2, HeLa, COLO205, CaCo2, B16F1, and HeK293t was inhibited by P. harmala hydrophilic extract with IC50 doses of 121.34 ± 1.71, 268.3 ± 0.75, 297.20 ± 1.00, 155.60 ± 1.14, 150.01 ± 0.51, 308.35 ± 0.53, 597.93 ± 1.36, and 5.38 ± 0.99 µg/ml, respectively. In addition, at 1000 µg/ml, 5-Fluorouracil reduced fibrosis cells by 0.089%, while the hydrophilic extract decreased the number of LX-2 cells by 5.81%. P. harmala plant-fixed oil exhibits potential antioxidant properties. While the hydrophilic extract showed limited effectiveness as an anti-α-amylase agent and demonstrated notable cytotoxic effects against various tested cancer cell lines. Furthermore, this extract significantly reduces the number of LX-2 fibrotic cells. These findings emphasize the therapeutic potential of these products in managing various health disorders and warrant further investigation into their mechanisms of action and clinical applications.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141936582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Antimalarial efficacy test of the aqueous crude leaf extract of Coriandrum sativum Linn.: an in vivo multiple model experimental study in mice infected with Plasmodium berghei 更正:芫荽水性粗叶提取物的抗疟功效测试:对感染了疟原虫的小鼠进行的体内多模型实验研究
2区 医学 Q1 Medicine Pub Date : 2024-08-01 DOI: 10.1186/s12906-024-04598-9
Getu Habte, Sisay Habte, Oda Jilo, Wondwosen Alemu, Kedir Eyasu, Welela Meka, Getabalew Shifera, Wubishet Gezimu, Milkias Dugasa, Sanbato Tamiru, Meta Mamo, Abiyot Kelecha

Correction: BMC Complement Med Ther 24, 267 (2024)

https://doi.org/10.1186/s12906-024-04577-0

Following publication of the original article [1], the authors reported an error in the author name of Abiyot Kelecha.

The incorrect author name is Abiyo Kelecha.

The correct author name is Abiyot Kelecha.

The author group has been updated above and the original article [1] has been corrected.

  1. 1. Habte, G., Habte, S., Jilo, O. et al Antimalarial efficacy test of the aqueous crude leaf extract of Coriandrum sativum Linn.: an in vivo multiple model experimental study in mice infected with Plasmodium berghei. BMC Complement Med Ther 24, 267 (2024). https://doi.org/10.1186/s12906-024-04577-0

Download references

Authors and Affiliations

  1. Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia

    Getu Habte & Wondwosen Alemu

  2. Department of Pharmacy, College of Health Sciences, Mattu University, P.O. Box 318, Mettu, Ethiopia

    Getu Habte & Oda Jilo

  3. Department of Biology, College of Natural and Computational Sciences, Ambo University, P.O. Box 19, Ambo, Ethiopia

    Sisay Habte

  4. Department of Computer Science, College of Engineering and Technology, Mattu University, P.O. Box 318, Mettu, Ethiopia

    Kedir Eyasu

  5. Department of Chemistry, College of Natural and Computational Sciences, Mattu University, P.O.Box 318, Mettu, Ethiopia

    Welela Meka, Getabalew Shifera, Meta Mamo & Abiyot Kelecha

  6. Department of Nursing, College of Health Sciences, Mattu University, P.O. Box 318, Mettu, Ethiopia

    Wubishet Gezimu, Milkias Dugasa & Sanbato Tamiru

Authors
  1. Getu HabteView author publications

    You can also search for this author in PubMed Google Scholar

  2. Sisay HabteView author publications

    You can also search for this author in PubMed Google Scholar

  3. Oda JiloView author publications

    You can also search for this author in PubMed Google Scholar

  4. Wondwosen AlemuView author publications

    You can also search for this author in PubMed Google Scholar

  5. Kedir EyasuView author publications

    You can also search for this author in PubMed Google Scholar

  6. Welela MekaView author
更正:BMC Complement Med Ther 24, 267 (2024)https://doi.org/10.1186/s12906-024-04577-0Following 原文[1]发表时,作者报告了Abiyot Kelecha的作者姓名有误。错误的作者姓名是Abiyo Kelecha。正确的作者姓名是Abiyot Kelecha。作者组别已在上文更新,原文[1]也已更正。1Habte, G., Habte, S., Jilo, O. et al Coriandrum sativum Linn.BMC Complement Med Ther 24, 267 (2024)。https://doi.org/10.1186/s12906-024-04577-0Download 参考文献作者及工作单位亚的斯亚贝巴大学健康科学学院药学院药理学与临床药学系,P.O. Box 1176, Addis Ababa University.Box 1176, Addis Ababa, EthiopiaGetu Habte & Wondwosen AlemuDepartment of Pharmacy, College of Health Sciences, Mattu University, P.O. Box 318, Mettu, EthiopiaGetu Habte & Oda JiloDepartment of Biology, College of Natural and Computational Sciences, Ambo University, P. O. Box 19, Ambo, EthiopiaGetu Habte & Oda JiloBox 19, Ambo, EthiopiaSisay HabteDepartment of Computer Science, College of Engineering and Technology, Mattu University, P.O. Box 318, Mettu, EthiopiaKedir EyasuDepartment of Chemistry, College of Natural and Computational Sciences, Mattu University, P.O.Box 318, Mettu, EthiopiaWelela Meka, Getabalew Shifera, Meta Mamo & Abiyot KelechaDepartment of Nursing, College of Health Sciences, Mattu University, P.O. Box 318, Mettu, EthiopiaWelela Meka, Getabalew Shifera, Meta Mamo & Abiyot Kelecha.Box 318, Mettu, EthiopiaWubishet Gezimu, Milkias Dugasa &;Sanbato TamiruAuthorsGetu HabteView Author publications您也可以在PubMed Google Scholar中搜索该作者Sisay HabteView Author publications您也可以在PubMed Google Scholar中搜索该作者Oda JiloView Author publications您也可以在PubMed Google Scholar中搜索该作者WondwosenAlemu查看作者发表的作品您也可以在 PubMed Google ScholarKedir Eyasu查看作者发表的作品您也可以在 PubMed Google ScholarWelela Meka查看作者发表的作品您也可以在 PubMed Google ScholarGetabalew Shifera查看作者发表的作品发表作品您也可以在 PubMed Google ScholarWubishet GezimuView 发表作品您也可以在 PubMed Google ScholarMilkias DugasaView 发表作品您也可以在 PubMed Google ScholarSanbato TamiruView 发表作品发表作品您也可以在PubMed Google Scholar中搜索该作者Meta Mamo查看作者发表作品您也可以在PubMed Google Scholar中搜索该作者Abiyot Kelecha查看作者发表作品您也可以在PubMed Google Scholar中搜索该作者通信作者Correspondence to Getu Habte.出版者注Springer Nature对已出版地图中的管辖权主张和机构隶属关系保持中立。原文的在线版本可在以下网址找到:https://doi.org/10.1186/s12906-024-04577-0.Open Access 本文采用知识共享署名 4.0 国际许可协议进行许可,该协议允许以任何媒介或格式使用、共享、改编、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,则您需要直接从版权所有者处获得许可。要查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/.Reprints and permissionsCite this articleHabte, G., Habte, S., Jilo, O. et al. Correction:Coriandrum sativum Linn.的粗叶水提取物的抗疟功效测试:对感染伯格氏疟原虫的小鼠进行的体内多模型实验研究。BMC Complement Med Ther 24, 292 (2024). https://doi.org/10.1186/s12906-024-04598-9Download citationPublished: 01 August 2024DOI: https://doi.org/10.1186/s12906-024-04598-9Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative.
{"title":"Correction: Antimalarial efficacy test of the aqueous crude leaf extract of Coriandrum sativum Linn.: an in vivo multiple model experimental study in mice infected with Plasmodium berghei","authors":"Getu Habte, Sisay Habte, Oda Jilo, Wondwosen Alemu, Kedir Eyasu, Welela Meka, Getabalew Shifera, Wubishet Gezimu, Milkias Dugasa, Sanbato Tamiru, Meta Mamo, Abiyot Kelecha","doi":"10.1186/s12906-024-04598-9","DOIUrl":"https://doi.org/10.1186/s12906-024-04598-9","url":null,"abstract":"<p><b>Correction: BMC Complement Med Ther 24, 267 (2024)</b></p><p><b>https://doi.org/10.1186/s12906-024-04577-0</b></p><p>Following publication of the original article [1], the authors reported an error in the author name of Abiyot Kelecha.</p><p>The incorrect author name is Abiyo Kelecha.</p><p>The correct author name is Abiyot Kelecha.</p><p>The author group has been updated above and the original article [1] has been corrected.</p><ol data-track-component=\"outbound reference\" data-track-context=\"references section\"><li data-counter=\"1.\"><p>1. Habte, G., Habte, S., Jilo, O. <i>et al</i> Antimalarial efficacy test of the aqueous crude leaf extract of <i>Coriandrum sativum</i> Linn.: an <i>in vivo</i> multiple model experimental study in mice infected with <i>Plasmodium berghei</i>. <i>BMC Complement Med Ther</i> <b>24</b>, 267 (2024). https://doi.org/10.1186/s12906-024-04577-0</p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia</p><p>Getu Habte &amp; Wondwosen Alemu</p></li><li><p>Department of Pharmacy, College of Health Sciences, Mattu University, P.O. Box 318, Mettu, Ethiopia</p><p>Getu Habte &amp; Oda Jilo</p></li><li><p>Department of Biology, College of Natural and Computational Sciences, Ambo University, P.O. Box 19, Ambo, Ethiopia</p><p>Sisay Habte</p></li><li><p>Department of Computer Science, College of Engineering and Technology, Mattu University, P.O. Box 318, Mettu, Ethiopia</p><p>Kedir Eyasu</p></li><li><p>Department of Chemistry, College of Natural and Computational Sciences, Mattu University, P.O.Box 318, Mettu, Ethiopia</p><p>Welela Meka, Getabalew Shifera, Meta Mamo &amp; Abiyot Kelecha</p></li><li><p>Department of Nursing, College of Health Sciences, Mattu University, P.O. Box 318, Mettu, Ethiopia</p><p>Wubishet Gezimu, Milkias Dugasa &amp; Sanbato Tamiru</p></li></ol><span>Authors</span><ol><li><span>Getu Habte</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Sisay Habte</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Oda Jilo</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Wondwosen Alemu</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Kedir Eyasu</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Welela Meka</span>View author ","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"211 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141867851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy, safety and mechanism of Simiaoyongan decoction in the treatment of carotid atherosclerotic plaque: a randomized, double-blind, placebo-controlled clinical trial protocol 四妙汤治疗颈动脉粥样硬化斑块的疗效、安全性和机制:随机、双盲、安慰剂对照临床试验方案
2区 医学 Q1 Medicine Pub Date : 2024-07-22 DOI: 10.1186/s12906-024-04555-6
QinHua Fan, ZhongJian Tan, WenQuan Su, QingXiao Li, Dian Jin, YaWei Du, LiPing Zhang, ShengXian Wu
Chronic inflammation is the major pathological feature of Atherosclerosis(As). Inflammation may accelerate plaque to develop, which is a key factor resulting in the thinning of the fibrous cap and the vulnerable rupture of plaque. Presently, clinical treatments are still lacking. It is necessary to find a safe and effective treatment for As inflammation. Simiaoyongan Decoction (SMYA) has potential anti-inflammatory and plaque protection effects. This protocol aims to evaluate the efficacy, safety, and mechanism of SMYA for patients with carotid atherosclerotic plaque. The assessment of SMYA clinical trial is designed as a randomized, double-blind, placebo-controlled study. The sample size is 86 cases in total, with 43 participants in the intervention group and the control group respectively. The intervention group takes SMYA, while the control group takes SMYA placebo. The medication lasts for 14 days every 10 weeks, with a total of 50 weeks. We will use carotid artery high resolution magnetic resonance imaging (HR-MRI) to measure plaque. The plaque minimum fiber cap thickness (PMFCT) is adopted as the primary outcome. The secondary outcomes include plaque fiber cap volume, volume percentage of fiber cap, lipid-rich necrotic core (LRNC) volume, volume percentage of LRNC, internal bleeding volume of plaque, internal bleeding volume percentage of plaque, plaque calcification volume, volume percentage of plaque calcification, lumen stenosis rate, average and a maximum of vessel wall thickness, vessel wall volume, total vessel wall load, carotid atherosclerosis score, hs-CRP, IL-1β and IL-6, the level of lipid profiles and blood glucose, blood pressure, and body weight. We anticipate that patients with As plaque will be improved from SMYA by inhibiting inflammation to enhance plaque stability. This study analyzes plaque by using HR-MRI to evaluate the clinical efficacy and safety of SMYA. Moreover, we conduct transcriptome analysis, proteomic analysis, and metagenomic analysis of blood and stool of participants to study the mechanism of SMYA against As plaque. This is the first prospective TCM trial to observe and treat As plaque by inhibiting inflammatory reaction directly. If successful, the finding will be valuable in the treatment of As plaque and drug development, especially in the “statin era”. This trial is registered on Chinese Clinical Trials.gov with number ChiCTR2000039062 on October 15, 2020 ( http://www.chictr.org.cn ).
慢性炎症是动脉粥样硬化(As)的主要病理特征。炎症可加速斑块形成,是导致纤维帽变薄和斑块易破裂的关键因素。目前,临床治疗方法仍然缺乏。因此,有必要找到一种安全有效的方法来治疗肛门炎症。辛夷坞煎剂(SMYA)具有潜在的抗炎和保护斑块的作用。本方案旨在评估SMYA对颈动脉粥样硬化斑块患者的疗效、安全性和机制。SMYA临床试验的评估设计为随机、双盲、安慰剂对照研究。样本量共86例,干预组和对照组各43例。干预组服用 SMYA,对照组服用 SMYA 安慰剂。疗程为每 10 周一次,每次 14 天,共 50 周。我们将使用颈动脉高分辨率磁共振成像(HR-MRI)来测量斑块。斑块最小纤维帽厚度(PMFCT)作为主要结果。次要结果包括斑块纤维帽体积、纤维帽体积百分比、富脂坏死核心(LRNC)体积、LRNC体积百分比、斑块内出血体积、斑块内出血体积百分比、斑块钙化体积、斑块钙化体积百分比、LRNC体积百分比、斑块钙化体积百分比、管腔狭窄率、血管壁厚度的平均值和最大值、血管壁体积、血管壁总负荷、颈动脉粥样硬化评分、hs-CRP、IL-1β 和 IL-6、血脂水平、血糖、血压和体重。我们预计,SMYA 将通过抑制炎症来增强斑块的稳定性,从而改善 As 斑块患者的病情。本研究通过使用 HR-MRI 对斑块进行分析,以评估 SMYA 的临床疗效和安全性。此外,我们还对参与者的血液和粪便进行转录组分析、蛋白质组分析和元基因组分析,以研究SMYA抗As斑块的机制。这是首个通过直接抑制炎症反应来观察和治疗As斑块的前瞻性中医药试验。如果研究成功,这一发现将对As斑块的治疗和药物开发具有重要价值,尤其是在 "他汀时代"。该试验已于2020年10月15日在中国临床试验网(China Clinical Trials.gov)注册,注册号为ChiCTR2000039062 ( http://www.chictr.org.cn )。
{"title":"Efficacy, safety and mechanism of Simiaoyongan decoction in the treatment of carotid atherosclerotic plaque: a randomized, double-blind, placebo-controlled clinical trial protocol","authors":"QinHua Fan, ZhongJian Tan, WenQuan Su, QingXiao Li, Dian Jin, YaWei Du, LiPing Zhang, ShengXian Wu","doi":"10.1186/s12906-024-04555-6","DOIUrl":"https://doi.org/10.1186/s12906-024-04555-6","url":null,"abstract":"Chronic inflammation is the major pathological feature of Atherosclerosis(As). Inflammation may accelerate plaque to develop, which is a key factor resulting in the thinning of the fibrous cap and the vulnerable rupture of plaque. Presently, clinical treatments are still lacking. It is necessary to find a safe and effective treatment for As inflammation. Simiaoyongan Decoction (SMYA) has potential anti-inflammatory and plaque protection effects. This protocol aims to evaluate the efficacy, safety, and mechanism of SMYA for patients with carotid atherosclerotic plaque. The assessment of SMYA clinical trial is designed as a randomized, double-blind, placebo-controlled study. The sample size is 86 cases in total, with 43 participants in the intervention group and the control group respectively. The intervention group takes SMYA, while the control group takes SMYA placebo. The medication lasts for 14 days every 10 weeks, with a total of 50 weeks. We will use carotid artery high resolution magnetic resonance imaging (HR-MRI) to measure plaque. The plaque minimum fiber cap thickness (PMFCT) is adopted as the primary outcome. The secondary outcomes include plaque fiber cap volume, volume percentage of fiber cap, lipid-rich necrotic core (LRNC) volume, volume percentage of LRNC, internal bleeding volume of plaque, internal bleeding volume percentage of plaque, plaque calcification volume, volume percentage of plaque calcification, lumen stenosis rate, average and a maximum of vessel wall thickness, vessel wall volume, total vessel wall load, carotid atherosclerosis score, hs-CRP, IL-1β and IL-6, the level of lipid profiles and blood glucose, blood pressure, and body weight. We anticipate that patients with As plaque will be improved from SMYA by inhibiting inflammation to enhance plaque stability. This study analyzes plaque by using HR-MRI to evaluate the clinical efficacy and safety of SMYA. Moreover, we conduct transcriptome analysis, proteomic analysis, and metagenomic analysis of blood and stool of participants to study the mechanism of SMYA against As plaque. This is the first prospective TCM trial to observe and treat As plaque by inhibiting inflammatory reaction directly. If successful, the finding will be valuable in the treatment of As plaque and drug development, especially in the “statin era”. This trial is registered on Chinese Clinical Trials.gov with number ChiCTR2000039062 on October 15, 2020 ( http://www.chictr.org.cn ).","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141745769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal plants used in multiple sclerosis patients, prevalence and associated factors: a descriptive cross-sectional study 多发性硬化症患者使用的药用植物、患病率及相关因素:一项描述性横断面研究
2区 医学 Q1 Medicine Pub Date : 2024-07-22 DOI: 10.1186/s12906-024-04587-y
Naemeh Nikvarz, Behnaz Sedighi, Mehdi Ansari, Shirin Shahdizade, Reyhane Shojaei, Fariba Sharififar
Multiple sclerosis (MS) is a chronic and debilitating disease that not only leads to disability and associated condition but also impacts one’s ability to maintain a professional life. People’s acceptance and utilization of medicinal plants (MPs) play an important role in managing their treatment process. As a result, this study aims to investigate the use of medicinal herbs among patients with MS. A descriptive cross-sectional study was conducted on 150 MS patients who visited a private clinic and the MS Association in Kerman, Iran in 2021. A questionnaire comprising questions about sociodemographic information, disease variables, and aspects of MPs usage was utilized for data collection. Statistical analysis was performed using SPSS version 20 (SPSS Inc., Chicago, IL). The Chi-square test was employed to identify any association between demographic characteristics and MPs usage. To determine the prevalence of plant use in a specific area and the consensus among informants, the use value (UV) and Informant consensus factor (Fic) were calculated. The study revealed a high prevalence of MPs usage among MS patients. Chamomile (66.6%) and golegavzaban (62.0%) were the most commonly used plants with the highest UV indices (0.88 and 0.82 respectively), while St. John’s wort and licorice were rarely used (0.67% and 4% respectively). Participants cited pursuing a healthier lifestyle as the primary reason for using MPs (24%). St. John’s wort, lavender, and chamomile were the most satisfying plants (100%, 100%, and 53.0% respectively). Chamomile had the highest Fic too. Most patients were motivated to get MPs from their relatives. Given the widespread use of MPs among MS patients, neurologists should enhance their knowledge in this area to guide patients away from seeking advice from non-professionals. Providing standardized formulations can help prevent potential interactions between MPs and mainstream drugs, thereby improving patients safety and outcomes.
多发性硬化症(MS)是一种使人衰弱的慢性疾病,不仅会导致残疾和相关病症,还会影响人们维持职业生活的能力。人们对药用植物(MPs)的接受和利用在治疗过程中发挥着重要作用。因此,本研究旨在调查多发性硬化症患者使用药用植物的情况。本研究对 2021 年在伊朗克尔曼一家私人诊所和多发性硬化症协会就诊的 150 名多发性硬化症患者进行了描述性横断面研究。数据收集采用了一份调查问卷,其中包括有关社会人口学信息、疾病变量和中草药使用方面的问题。统计分析使用 SPSS 版本 20(SPSS Inc.)采用卡方检验来确定人口统计学特征与 MPs 使用之间的关联。为了确定特定地区植物使用的普遍程度以及信息提供者之间的共识,计算了使用价值(UV)和信息提供者共识因子(Fic)。研究显示,多发性硬化症患者使用主要植物的比例很高。洋甘菊(66.6%)和鹅掌楸(62.0%)是最常用的植物,其 UV 指数最高(分别为 0.88 和 0.82),而圣约翰草和甘草则很少使用(分别为 0.67% 和 4%)。参与者认为追求更健康的生活方式是使用 MPs 的主要原因(24%)。圣约翰草、薰衣草和洋甘菊是最令人满意的植物(分别为 100%、100% 和 53.0%)。洋甘菊的 Fic 值也最高。大多数患者都希望从亲戚那里获得 MPs。鉴于多发性硬化症患者广泛使用 MPs,神经科医生应加强这方面的知识,引导患者避免向非专业人员寻求建议。提供标准化制剂有助于防止 MPs 与主流药物之间的潜在相互作用,从而提高患者的安全性和治疗效果。
{"title":"Medicinal plants used in multiple sclerosis patients, prevalence and associated factors: a descriptive cross-sectional study","authors":"Naemeh Nikvarz, Behnaz Sedighi, Mehdi Ansari, Shirin Shahdizade, Reyhane Shojaei, Fariba Sharififar","doi":"10.1186/s12906-024-04587-y","DOIUrl":"https://doi.org/10.1186/s12906-024-04587-y","url":null,"abstract":"Multiple sclerosis (MS) is a chronic and debilitating disease that not only leads to disability and associated condition but also impacts one’s ability to maintain a professional life. People’s acceptance and utilization of medicinal plants (MPs) play an important role in managing their treatment process. As a result, this study aims to investigate the use of medicinal herbs among patients with MS. A descriptive cross-sectional study was conducted on 150 MS patients who visited a private clinic and the MS Association in Kerman, Iran in 2021. A questionnaire comprising questions about sociodemographic information, disease variables, and aspects of MPs usage was utilized for data collection. Statistical analysis was performed using SPSS version 20 (SPSS Inc., Chicago, IL). The Chi-square test was employed to identify any association between demographic characteristics and MPs usage. To determine the prevalence of plant use in a specific area and the consensus among informants, the use value (UV) and Informant consensus factor (Fic) were calculated. The study revealed a high prevalence of MPs usage among MS patients. Chamomile (66.6%) and golegavzaban (62.0%) were the most commonly used plants with the highest UV indices (0.88 and 0.82 respectively), while St. John’s wort and licorice were rarely used (0.67% and 4% respectively). Participants cited pursuing a healthier lifestyle as the primary reason for using MPs (24%). St. John’s wort, lavender, and chamomile were the most satisfying plants (100%, 100%, and 53.0% respectively). Chamomile had the highest Fic too. Most patients were motivated to get MPs from their relatives. Given the widespread use of MPs among MS patients, neurologists should enhance their knowledge in this area to guide patients away from seeking advice from non-professionals. Providing standardized formulations can help prevent potential interactions between MPs and mainstream drugs, thereby improving patients safety and outcomes.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"92 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141737304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated network pharmacology and metabolomics to reveal the mechanism of Pinellia ternata inhibiting non-small cell lung cancer cells 综合网络药理学和代谢组学揭示半夏抑制非小细胞肺癌细胞的机制
2区 医学 Q1 Medicine Pub Date : 2024-07-11 DOI: 10.1186/s12906-024-04574-3
Fan Feng, Ping Hu, Lei Peng, Lisheng Xu, Jun Chen, Qiong Chen, Xingtao Zhang, Xingkui Tao
Lung cancer is a malignant tumor with highly heterogeneous characteristics. A classic Chinese medicine, Pinellia ternata (PT), was shown to exert therapeutic effects on lung cancer cells. However, its chemical and pharmacological profiles are not yet understood. In the present study, we aimed to reveal the mechanism of PT in treating lung cancer cells through metabolomics and network pharmacology. Metabolomic analysis of two strains of lung cancer cells treated with Pinellia ternata extracts (PTE) was used to identify differentially abundant metabolites, and the metabolic pathways associated with the DEGs were identified by MetaboAnalyst. Then, network pharmacology was applied to identify potential targets against PTE-induced lung cancer cells. The integrated network of metabolomics and network pharmacology was constructed based on Cytoscape. PTE obviously inhibited the proliferation, migration and invasion of A549 and NCI-H460 cells. The results of the cellular metabolomics analysis showed that 30 metabolites were differentially expressed in the lung cancer cells of the experimental and control groups. Through pathway enrichment analysis, 5 metabolites were found to be involved in purine metabolism, riboflavin metabolism and the pentose phosphate pathway, including D-ribose 5-phosphate, xanthosine, 5-amino-4-imidazolecarboxyamide, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). Combined with network pharmacology, 11 bioactive compounds were found in PT, and networks of bioactive compound–target gene–metabolic enzyme–metabolite interactions were constructed. In conclusion, this study revealed the complicated mechanisms of PT against lung cancer. Our work provides a novel paradigm for identifying the potential mechanisms underlying the pharmacological effects of natural compounds.
肺癌是一种具有高度异质性的恶性肿瘤。一种经典中药--半夏(PT)被证明对肺癌细胞有治疗作用。然而,人们对其化学成分和药理作用还不甚了解。本研究旨在通过代谢组学和网络药理学揭示半夏治疗肺癌细胞的机制。通过对两株经半夏提取物(PTE)处理的肺癌细胞进行代谢组学分析,鉴定出差异丰富的代谢物,并通过MetaboAnalyst鉴定出与DEGs相关的代谢通路。然后,应用网络药理学鉴定了针对 PTE 诱导的肺癌细胞的潜在靶点。基于Cytoscape构建了代谢组学和网络药理学的整合网络。PTE明显抑制了A549和NCI-H460细胞的增殖、迁移和侵袭。细胞代谢组学分析结果表明,30种代谢物在实验组和对照组肺癌细胞中存在差异表达。通过通路富集分析,发现5种代谢物参与了嘌呤代谢、核黄素代谢和磷酸戊糖通路,包括D-核糖-5-磷酸、黄嘌呤核苷、5-氨基-4-咪唑羧酰胺、黄素单核苷酸(FMN)和黄素腺嘌呤二核苷酸(FAD)。结合网络药理学,在 PT 中发现了 11 种生物活性化合物,并构建了生物活性化合物-靶基因-代谢酶-代谢物的相互作用网络。总之,这项研究揭示了 PT 抗肺癌的复杂机制。我们的工作为确定天然化合物药理作用的潜在机制提供了一个新的范例。
{"title":"Integrated network pharmacology and metabolomics to reveal the mechanism of Pinellia ternata inhibiting non-small cell lung cancer cells","authors":"Fan Feng, Ping Hu, Lei Peng, Lisheng Xu, Jun Chen, Qiong Chen, Xingtao Zhang, Xingkui Tao","doi":"10.1186/s12906-024-04574-3","DOIUrl":"https://doi.org/10.1186/s12906-024-04574-3","url":null,"abstract":"Lung cancer is a malignant tumor with highly heterogeneous characteristics. A classic Chinese medicine, Pinellia ternata (PT), was shown to exert therapeutic effects on lung cancer cells. However, its chemical and pharmacological profiles are not yet understood. In the present study, we aimed to reveal the mechanism of PT in treating lung cancer cells through metabolomics and network pharmacology. Metabolomic analysis of two strains of lung cancer cells treated with Pinellia ternata extracts (PTE) was used to identify differentially abundant metabolites, and the metabolic pathways associated with the DEGs were identified by MetaboAnalyst. Then, network pharmacology was applied to identify potential targets against PTE-induced lung cancer cells. The integrated network of metabolomics and network pharmacology was constructed based on Cytoscape. PTE obviously inhibited the proliferation, migration and invasion of A549 and NCI-H460 cells. The results of the cellular metabolomics analysis showed that 30 metabolites were differentially expressed in the lung cancer cells of the experimental and control groups. Through pathway enrichment analysis, 5 metabolites were found to be involved in purine metabolism, riboflavin metabolism and the pentose phosphate pathway, including D-ribose 5-phosphate, xanthosine, 5-amino-4-imidazolecarboxyamide, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). Combined with network pharmacology, 11 bioactive compounds were found in PT, and networks of bioactive compound–target gene–metabolic enzyme–metabolite interactions were constructed. In conclusion, this study revealed the complicated mechanisms of PT against lung cancer. Our work provides a novel paradigm for identifying the potential mechanisms underlying the pharmacological effects of natural compounds.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141586519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolation and anti-neuroinflammation activity of sesquiterpenoids from Artemisia argyi: computational simulation and experimental verification 艾蒿倍半萜化合物的分离和抗神经发炎活性:计算模拟和实验验证
2区 医学 Q1 Medicine Pub Date : 2024-07-11 DOI: 10.1186/s12906-024-04578-z
Caiwenjie La, Menghe Li, Zexu Wang, Tao Liu, Qiongzhen Zeng, Pinghua Sun, Zhe Ren, Cuifang Ye, Qiuying Liu, Yifei Wang
Artemisia argyi is a traditional herbal medicine belonging to the genus Artemisia that plays an important role in suppressing inflammation. However, the chemical constituents and underlying mechanisms of its therapeutic potential in neuroinflammation are still incompletely understood, and warrant further investigation. Several column chromatography were employed to isolate and purify chemical constituents from Artemisia argyi, and modern spectroscopy techniques were used to elucidate their chemical structures. The screening of monomeric compounds with nitric oxide inhibition led to the identification of the most effective bioactive compound, which was subsequently confirmed for its anti-inflammatory capability through qRT‒PCR. Predictions of compound-target interactions were made using the PharmMapper webserver and the TargetNet database, and an integrative protein-protein interaction network was constructed by intersecting the predicted targets with neuroinflammation-related targets. Topological analysis was performed to identify core targets, and molecular docking and molecular dynamics simulations were utilized to validate the findings. The result of the molecular simulations was experimentally validated through drug affinity responsive target stability (DARTS) and Western blot experiments. Seventeen sesquiterpenoids, including fifteen known sesquiterpenoids and two newly discovered guaiane-type sesquiterpenoids (argyinolide S and argyinolide T) were isolated from Artemisia argyi. Bioactivity screening revealed that argyinolide S (AS) possessed the most potent anti-inflammatory activity. However, argyinolide T (AT) showed weak anti-inflammatory activity, so AS was the target compound for further study. AS may regulate neuroinflammation through its modulation of eleven core targets: protein kinase B 1 (AKT1), epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein Kinase (FYN), Janus Kinase (JAK) 1, mitogen-activated protein (MAP) Kinase 1,8 and 14, matrix metalloproteinase 9 (MMP9), ras-related C3 botulinum toxin substrate 1 (RAC1), nuclear factor kappa-B p65 (RELA), and retinoid X receptor alpha (RXRA). Molecular dynamics simulations and DARTS experiments confirmed the stable binding of AS to JAK1, and Western blot experiments demonstrated the ability of AS to inhibit the phosphorylation of downstream Signal transducer and activator of transcription 3 (STAT3) mediated by JAK1. The sesquiterpenoid compounds isolated from Artemisia argyi, exhibit significant inhibitory effects on inflammation in C57BL/6 murine microglia cells (BV-2). Among these compounds, AS, a newly discovered guaiane-type sesquiterpenoid in Artemisia argyi, has been demonstrated to effectively inhibit the occurrence of neuroinflammation by targeting JAK1.
青蒿是属于蒿属的一种传统草药,在抑制炎症方面发挥着重要作用。然而,人们对其化学成分及其治疗神经炎症的潜在机制仍不甚了解,有待进一步研究。研究人员采用多种柱层析方法从青蒿中分离和纯化化学成分,并利用现代光谱技术阐明其化学结构。通过筛选具有一氧化氮抑制作用的单体化合物,确定了最有效的生物活性化合物,随后通过 qRT-PCR 验证了其抗炎能力。利用PharmMapper网络服务器和TargetNet数据库对化合物与靶点的相互作用进行了预测,并通过将预测的靶点与神经炎症相关靶点相交,构建了一个整合的蛋白质-蛋白质相互作用网络。通过拓扑分析确定了核心靶点,并利用分子对接和分子动力学模拟验证了研究结果。分子模拟的结果通过药物亲和力反应靶点稳定性(DARTS)和 Western 印迹实验进行了实验验证。从青蒿中分离出17个倍半萜类化合物,包括15个已知倍半萜类化合物和两个新发现的愈创木型倍半萜类化合物(argyinolide S和argyinolide T)。生物活性筛选显示,阿基内酯 S(AS)具有最强的抗炎活性。然而,青蒿内酯 T(AT)的抗炎活性较弱,因此 AS 成为进一步研究的目标化合物。AS可能通过调节11个核心靶点来调节神经炎症:蛋白激酶 B 1 (AKT1)、表皮生长因子受体 (EGFR)、原癌基因酪氨酸蛋白激酶 (FYN)、Janus 激酶 (JAK) 1、丝裂原活化蛋白 (MAP) 激酶 1、8 和 14、基质金属蛋白酶 9 (MMP9)、ras 相关 C3 肉毒毒素底物 1 (RAC1)、核因子 kappa-B p65 (RELA) 和视黄醇 X 受体 alpha (RXRA)。分子动力学模拟和 DARTS 实验证实了 AS 与 JAK1 的稳定结合,而 Western 印迹实验则证明 AS 能够抑制由 JAK1 介导的下游信号转导子和转录激活子 3(STAT3)的磷酸化。从艾蒿中分离出的倍半萜化合物对 C57BL/6 小鼠小胶质细胞(BV-2)的炎症有显著的抑制作用。在这些化合物中,青蒿中新发现的瓜蒌类倍半萜化合物 AS 被证明能通过靶向 JAK1 有效抑制神经炎症的发生。
{"title":"Isolation and anti-neuroinflammation activity of sesquiterpenoids from Artemisia argyi: computational simulation and experimental verification","authors":"Caiwenjie La, Menghe Li, Zexu Wang, Tao Liu, Qiongzhen Zeng, Pinghua Sun, Zhe Ren, Cuifang Ye, Qiuying Liu, Yifei Wang","doi":"10.1186/s12906-024-04578-z","DOIUrl":"https://doi.org/10.1186/s12906-024-04578-z","url":null,"abstract":"Artemisia argyi is a traditional herbal medicine belonging to the genus Artemisia that plays an important role in suppressing inflammation. However, the chemical constituents and underlying mechanisms of its therapeutic potential in neuroinflammation are still incompletely understood, and warrant further investigation. Several column chromatography were employed to isolate and purify chemical constituents from Artemisia argyi, and modern spectroscopy techniques were used to elucidate their chemical structures. The screening of monomeric compounds with nitric oxide inhibition led to the identification of the most effective bioactive compound, which was subsequently confirmed for its anti-inflammatory capability through qRT‒PCR. Predictions of compound-target interactions were made using the PharmMapper webserver and the TargetNet database, and an integrative protein-protein interaction network was constructed by intersecting the predicted targets with neuroinflammation-related targets. Topological analysis was performed to identify core targets, and molecular docking and molecular dynamics simulations were utilized to validate the findings. The result of the molecular simulations was experimentally validated through drug affinity responsive target stability (DARTS) and Western blot experiments. Seventeen sesquiterpenoids, including fifteen known sesquiterpenoids and two newly discovered guaiane-type sesquiterpenoids (argyinolide S and argyinolide T) were isolated from Artemisia argyi. Bioactivity screening revealed that argyinolide S (AS) possessed the most potent anti-inflammatory activity. However, argyinolide T (AT) showed weak anti-inflammatory activity, so AS was the target compound for further study. AS may regulate neuroinflammation through its modulation of eleven core targets: protein kinase B 1 (AKT1), epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein Kinase (FYN), Janus Kinase (JAK) 1, mitogen-activated protein (MAP) Kinase 1,8 and 14, matrix metalloproteinase 9 (MMP9), ras-related C3 botulinum toxin substrate 1 (RAC1), nuclear factor kappa-B p65 (RELA), and retinoid X receptor alpha (RXRA). Molecular dynamics simulations and DARTS experiments confirmed the stable binding of AS to JAK1, and Western blot experiments demonstrated the ability of AS to inhibit the phosphorylation of downstream Signal transducer and activator of transcription 3 (STAT3) mediated by JAK1. The sesquiterpenoid compounds isolated from Artemisia argyi, exhibit significant inhibitory effects on inflammation in C57BL/6 murine microglia cells (BV-2). Among these compounds, AS, a newly discovered guaiane-type sesquiterpenoid in Artemisia argyi, has been demonstrated to effectively inhibit the occurrence of neuroinflammation by targeting JAK1.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141586488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of essential oil of Origanum onites and its major component carvacrol on the expression of toxicity pathway genes in HepG2 cells 牛至精油及其主要成分香芹酚对 HepG2 细胞毒性通路基因表达的影响
2区 医学 Q1 Medicine Pub Date : 2024-07-11 DOI: 10.1186/s12906-024-04571-6
Özlem Tomsuk, Victor Kuete, Hülya Sivas, Mine Kürkçüoğlu
Origanum species have been used in various commercial constructions as a remedy against burns and wounds, agriculture, alcoholic drinks, fragrance, and flavoring substances of food products. The essential oil of Origanum onites L. (EOOO) and its component carvacrol (CV) possesses a wide range of biological activities including anti-cancer activity. The purpose of this study was to investigate the growth inhibitory activity of the essential oil and its major component CV and then hepatotoxicity pathway-related genes in HepG2 cells. The effects of the EOOO and CV on cell growth and mRNA expressions of 84 hepatotoxicity pathway-related genes were investigated in HepG2, using trypan blue exclusion/ bromodeoxyuridine (BrdU) incorporation tests and real-time-polymerase chain reaction (RT-PCR) array, respectively. The EOOO and CV inhibited cell growth with IC50 values of 0.08 µg/mL and 45 µg/mL, respectively, after 24 h. Real-time, reverse-transcription-polymerase chain reaction (RT2-PCR) array analysis revealed that expressions of 32 genes out of 84 were changed at least 2-fold or more in the EOOO-treated cells. Among them, expression levels of 17 genes were elevated, while expression levels of 15 genes were diminished. Furthermore, after exposure of cells to 45 µg/mL of CV, the expression of 8 genes was increased while the other 8 genes were decreased. Both the EOOO and carvacrol affected the expression of 48 genes of HepG2 cells which are involved in the hepatotoxicity pathway, indicating their hepatoprotective and possible anti-hepatocarcinogenic effects. The present study demonstrates that the essential oil of Origanum onites and carvacrol can be used in various applications such as anticancer or herbal drugs, since its non-hepatotoxicity.
牛至品种在各种商业建筑中被用作治疗烧伤和创伤、农业、酒精饮料、香料和食品调味物质。牛至精油(EOOO)及其成分香芹酚(CV)具有广泛的生物活性,包括抗癌活性。本研究的目的是调查牛至精油及其主要成分 CV 的生长抑制活性,以及 HepG2 细胞中的肝毒性通路相关基因。研究采用胰蓝排除/溴脱氧尿苷(BrdU)掺入试验和实时聚合酶链反应(RT-PCR)阵列,分别检测了 EOOO 和 CV 对 HepG2 细胞生长和 84 个肝毒性通路相关基因 mRNA 表达的影响。实时反转录聚合酶链反应(RT2-PCR)阵列分析表明,84 个基因中有 32 个基因的表达在 EOOO 处理的细胞中发生了至少 2 倍或以上的变化。其中,17 个基因的表达水平升高,15 个基因的表达水平降低。此外,细胞暴露于 45 微克/毫升的 CV 后,8 个基因的表达水平升高,而另外 8 个基因的表达水平降低。香叶精油和香芹酚都影响了 HepG2 细胞中参与肝毒性途径的 48 个基因的表达,这表明它们具有保肝作用,并可能具有抗肝癌作用。本研究表明,牛至精油和香芹酚具有非肝脏毒性,可用于抗癌或草药等多种用途。
{"title":"Effects of essential oil of Origanum onites and its major component carvacrol on the expression of toxicity pathway genes in HepG2 cells","authors":"Özlem Tomsuk, Victor Kuete, Hülya Sivas, Mine Kürkçüoğlu","doi":"10.1186/s12906-024-04571-6","DOIUrl":"https://doi.org/10.1186/s12906-024-04571-6","url":null,"abstract":"Origanum species have been used in various commercial constructions as a remedy against burns and wounds, agriculture, alcoholic drinks, fragrance, and flavoring substances of food products. The essential oil of Origanum onites L. (EOOO) and its component carvacrol (CV) possesses a wide range of biological activities including anti-cancer activity. The purpose of this study was to investigate the growth inhibitory activity of the essential oil and its major component CV and then hepatotoxicity pathway-related genes in HepG2 cells. The effects of the EOOO and CV on cell growth and mRNA expressions of 84 hepatotoxicity pathway-related genes were investigated in HepG2, using trypan blue exclusion/ bromodeoxyuridine (BrdU) incorporation tests and real-time-polymerase chain reaction (RT-PCR) array, respectively. The EOOO and CV inhibited cell growth with IC50 values of 0.08 µg/mL and 45 µg/mL, respectively, after 24 h. Real-time, reverse-transcription-polymerase chain reaction (RT2-PCR) array analysis revealed that expressions of 32 genes out of 84 were changed at least 2-fold or more in the EOOO-treated cells. Among them, expression levels of 17 genes were elevated, while expression levels of 15 genes were diminished. Furthermore, after exposure of cells to 45 µg/mL of CV, the expression of 8 genes was increased while the other 8 genes were decreased. Both the EOOO and carvacrol affected the expression of 48 genes of HepG2 cells which are involved in the hepatotoxicity pathway, indicating their hepatoprotective and possible anti-hepatocarcinogenic effects. The present study demonstrates that the essential oil of Origanum onites and carvacrol can be used in various applications such as anticancer or herbal drugs, since its non-hepatotoxicity.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141586487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic profiling and enzyme inhibitory activity of the essential oil of citrus aurantium fruit peel 枳壳果皮精油的代谢谱分析和酶抑制活性
2区 医学 Q1 Medicine Pub Date : 2024-07-10 DOI: 10.1186/s12906-024-04505-2
Naglaa S. Ashmawy, Nilofar Nilofar, Gokhan Zengin, Omayma A. Eldahshan
Bitter orange (Citrus aurantium) is a fruiting shrub native to tropical and subtropical countries around the world and cultivated in many regions due to its nutraceutical value. The current study investigated the metabolic profiling and enzyme inhibitory activities of volatile constituents derived from the C. aurantium peel cultivated in Egypt by three different extraction methods. The volatile chemical constituents of the peel of C. aurantium were isolated using three methods; steam distillation (SD), hydrodistillation (HD), and microwave-assisted hydrodistillation (MAHD), and then were investigated by GC-MS. The antioxidant potential was evaluated by different assays such as DPPH, ABTS, FRAP, CUPRAC, and phosphomolybdenum and metal chelating potential. Moreover, the effect of enzyme inhibition of the three essential oils was tested using BChE, AChE, tyrosinase, glucosidase, as well as amylase assays. A total of six compounds were detected by GC/MS analysis. The major constituent obtained by all three extraction methods was limonene (98.86% by SD, 98.68% by HD, and 99.23% by MAHD). Differences in the composition of the compounds of the three oils were observed. The hydrodistillation technique has yielded the highest number of compounds, notably two oxygenated monoterpenes: linalool (0.12%) and α-terpineol acetate (0.1%). In our study differences in the extraction methods of C. aurantium peel oils resulted in differences in the oils’ chemical composition. Citrus essential oils and their components showed potential antioxidant, anticholinesterase, antimelanogenesis, and antidiabetic activities. The presence of linalool and α-terpineol acetate may explain the superior activity observed for the oil isolated by HD in both radical scavenging and AChE inhibition assays, as well as in the enzyme inhibition assays.
苦橙(Citrus aurantium)是一种果实灌木,原产于世界各地的热带和亚热带国家,因其营养保健价值而在许多地区种植。本研究通过三种不同的提取方法,研究了从埃及栽培的苦橙果皮中提取的挥发性成分的代谢谱分析和酶抑制活性。本研究采用蒸汽蒸馏(SD)、水蒸馏(HD)和微波辅助水蒸馏(MAHD)三种方法分离了枳壳果皮中的挥发性化学成分,然后用气相色谱-质谱(GC-MS)对其进行了研究。通过 DPPH、ABTS、FRAP、CUPRAC、磷钼和金属螯合潜力等不同检测方法对其抗氧化潜力进行了评估。此外,还使用 BChE、AChE、酪氨酸酶、葡萄糖苷酶和淀粉酶检测了三种精油的酶抑制效果。通过气相色谱/质谱分析,共检测到六种化合物。三种提取方法得到的主要成分都是柠檬烯(SD 提取率为 98.86%,HD 提取率为 98.68%,MAHD 提取率为 99.23%)。三种油的化合物组成存在差异。水蒸馏技术产生的化合物数量最多,尤其是两种含氧单萜烯:芳樟醇(0.12%)和α-松油醇乙酸酯(0.1%)。在我们的研究中,枳壳皮精油提取方法的不同导致了精油化学成分的不同。柑橘精油及其成分具有潜在的抗氧化、抗胆碱酯酶、抗黑色素生成和抗糖尿病活性。芳樟醇和α-松油醇乙酸酯的存在可能是通过 HD 分离出的精油在自由基清除和 AChE 抑制试验以及酶抑制试验中具有更高活性的原因。
{"title":"Metabolic profiling and enzyme inhibitory activity of the essential oil of citrus aurantium fruit peel","authors":"Naglaa S. Ashmawy, Nilofar Nilofar, Gokhan Zengin, Omayma A. Eldahshan","doi":"10.1186/s12906-024-04505-2","DOIUrl":"https://doi.org/10.1186/s12906-024-04505-2","url":null,"abstract":"Bitter orange (Citrus aurantium) is a fruiting shrub native to tropical and subtropical countries around the world and cultivated in many regions due to its nutraceutical value. The current study investigated the metabolic profiling and enzyme inhibitory activities of volatile constituents derived from the C. aurantium peel cultivated in Egypt by three different extraction methods. The volatile chemical constituents of the peel of C. aurantium were isolated using three methods; steam distillation (SD), hydrodistillation (HD), and microwave-assisted hydrodistillation (MAHD), and then were investigated by GC-MS. The antioxidant potential was evaluated by different assays such as DPPH, ABTS, FRAP, CUPRAC, and phosphomolybdenum and metal chelating potential. Moreover, the effect of enzyme inhibition of the three essential oils was tested using BChE, AChE, tyrosinase, glucosidase, as well as amylase assays. A total of six compounds were detected by GC/MS analysis. The major constituent obtained by all three extraction methods was limonene (98.86% by SD, 98.68% by HD, and 99.23% by MAHD). Differences in the composition of the compounds of the three oils were observed. The hydrodistillation technique has yielded the highest number of compounds, notably two oxygenated monoterpenes: linalool (0.12%) and α-terpineol acetate (0.1%). In our study differences in the extraction methods of C. aurantium peel oils resulted in differences in the oils’ chemical composition. Citrus essential oils and their components showed potential antioxidant, anticholinesterase, antimelanogenesis, and antidiabetic activities. The presence of linalool and α-terpineol acetate may explain the superior activity observed for the oil isolated by HD in both radical scavenging and AChE inhibition assays, as well as in the enzyme inhibition assays.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141574995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMC Complementary and Alternative Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1